MARKET

BLRX

BLRX

BioLine RX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.000
-0.110
-5.21%
Closed 16:51 08/11 EDT
OPEN
2.120
PREV CLOSE
2.110
HIGH
2.120
LOW
1.970
VOLUME
253.49K
TURNOVER
--
52 WEEK HIGH
3.642
52 WEEK LOW
1.061
MARKET CAP
39.53M
P/E (TTM)
-0.8476
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BLRX stock price target is 11.33 with a high estimate of 18.00 and a low estimate of 5.00.

EPS

BLRX News

More
BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended June 30, 2020 and provides a corporate update.
PR Newswire · 5d ago
BioLineRx Granted Australian Patent Number 2014343214 Titled 'Methods of treating acute myeloid leukemia with a FLT3 mutation'
https://pericles.ipaustralia.gov.au/ols/auspat/applicationDetails.do?applicationNo=2014343214#
Benzinga · 6d ago
BioLineRx to Report Second Quarter 2020 Results on August 6, 2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended June 30, 2020 on Thursday, August 6, 2020, before the US mark
PR Newswire · 07/31 11:00
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Benzinga · 07/26 13:55
BioLineRx (BLRX) to Report Q2 Earnings: What's in the Cards?
BioLineRx (BLRX) will provide updates on its clinical programs when it releases second-quarter 2020 results.
Zacks · 07/24 17:08
Aclaris (ACRS) Surges: Stock Moves 5.4% Higher
Zacks · 07/08 13:43
Acceleron (XLRN) in Focus: Stock Moves 5.3% Higher
Zacks · 07/06 13:50
Zogenix (ZGNX) in Focus: Stock Moves 7.6% Higher
Zacks · 07/02 13:53

Industry

Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-0.89%

Hot Stocks

Symbol
Price
%Change

About BLRX

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
More

Webull offers kinds of BioLineRX Ltd. stock information, including NASDAQ:BLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLRX stock methods without spending real money on the virtual paper trading platform.